FrancophonIA/ELRC3.0 huggingface dataset:
English: • fever, chest pain, increased heart rate, decreased blood pressure, shortness of breath or rapid breathing (signs of blood poisoning, which is also known as sepsis)
Danish: • feber, brystsmerter, hurtig hjerterytme, nedsat blodtryk, kortåndethed eller hurtig vejrtrækning (tegn på blodforgiftning, som også kaldes sepsis)
English: Patients received panobinostat (20 mg taken orally once a day, three times per week, on a 2 weeks on and 1 week off dosing regimen), in combination with bortezomib (1.3 mg/m2 injected intravenously) and dexamethasone (20 mg).
Danish: Patienterne fik panobinostat (20 mg indtaget oralt én gang dagligt tre gange om ugen i et doseringsregime med 2 uger med behandling og 1 uge uden behandling), i kombination med bortezomib (1,3 mg/m2 injiceret intravenøst) og dexamethason (20 mg).
English: Panobinostat is administered in combination with bortezomib and dexamethasone, as shown in Tables 1 and 2.
Danish: Panobinostat administreres i kombination med bortezomib og dexamethason som vist i tabel 1 og 2.
English: The platelet count should be ≥100 x 109/l and the absolute neutrophil count ≥1.0 x 109/l prior to initiation of treatment.
Danish: Trombocyttallet bør være ≥100 x 109/l og det absolutte neutrofiltal ≥1,0 x 109/l før behandlingsinitiering.
English: - For women taking Farydak
Danish: - Til kvinder, der tager Farydak
English: • difficulty in breathing or swallowing, swelling of the face, lips, tongue or throat, severe itching of the skin, with a red rash or raised bumps (potential signs of an allergic reaction)
Danish: • problemer med at trække vejret eller synke, hævelse af ansigt, læber, tunge eller hals, alvorlig hudkløe med rødt udslæt eller knopper (mulige tegn på en allergisk reaktion)
English: Fluid and electrolyte blood levels, especially potassium, magnesium and phosphate, should be monitored periodically during therapy and corrected as clinically indicated to prevent potential dehydration and electrolyte disturbances (see section 4.2).
Danish: Væske- og elektrolytniveauer i blodet, særlig kalium, magnesium og fosfat, bør monitoreres periodisk under behandlingen og korrigeres ifølge klinisk indikation for at forebygge potentiel dehydrering og elektrolytforstyrrelse (se pkt.
English: - Pregnancy
Danish: - Graviditet
English: PAN= panobinostat PBO= placebo BTZ= bortezomib Dex = dexamethasone
Danish: PAN= panobinostat PBO= placebo BTZ= bortezomib Dex = dexamethason
English: • sudden and crushing chest pain, feeling tired, irregular heartbeat (potential signs of a heart attack)
Danish: • pludselige og knugende brystsmerter, træthed, uregelmæssig hjerterytme (mulige tegn på et hjerteanfald)
English: • chest pain or discomfort, changes in heartbeat (faster or slower), palpitations, light-headedness, fainting, dizziness, blue discolouration of your lips, shortness of breath, swelling of lower limbs or skin (signs of heart problems)
Danish: • brystsmerter eller -ubehag, ændringer i hjerterytmen (hurtigere eller langsommere), hjertebanken, ørhed, besvimelse, svimmelhed, blå misfarvning af læberne, kortåndethed, hævelse af benene eller huden (tegn på hjerteproblemer)
English: The safety data reported below are based on the phase III clinical study (Panorama 1) in 381 patients with multiple myeloma treated with 20 mg panobinostat once a day three times per week, on a 2 weeks on and 1 week off dosing regimen in combination with bortezomib and dexamethasone.
Danish: De sikkerhedsdata, der gengives herunder, er baseret på det kliniske fase III-forsøg (Panorama 1) hos 381 patienter med myelomatose, der blev behandlet med 20 mg panobinostat én gang dagligt tre gange om ugen i et doseringsregime med 2 uger med behandling og 1 uge uden behandling i kombination med bortezomib og dexamethason.
English: • vomiting blood, black or bloody stools, passage of fresh blood through the anus, usually in or with stools (signs of gastrointestinal bleeding)
Danish: • opkastning af blod, sort eller blodig afføring, frisk blod fra endetarmen, som regel i eller sammen med afføringen (tegn på mave-tarmblødning)
English: - Breast-feeding You should not take Farydak if you are breast-feeding.
Danish: - Amning Du må ikke tage Farydak, hvis du ammer.
English: • feeling thirsty, high urine output, increased appetite with weight loss (signs of a high level of sugar in the blood)
Danish: • tørst, stor urinmængde, øget appetit med vægttab (tegn på højt blodsukker)
English: For patients >75 years of age, depending on the patient's general condition and concomitant diseases, an adjustment of the starting doses or schedule of the components of the combination regimen may be considered.
Danish: For patienter >75 år kan justering af startdosis eller af planen for kombinationsbehandlingens komponenter overvejes afhængig af patientens almentilstand og samtidige sygdomme.
English: Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.
Danish: Inden for hver enkelt frekvensgruppe skal bivirkningerne opstilles efter, hvor alvorlige de er.
English: The capsules should be swallowed whole with water, with or without food (see section 5.2), and they should not be opened, crushed or chewed.
Danish: Kapslerne skal sluges hele med indtagelse af vand med eller uden mad (se pkt.
English: Thyroid and pituitary function should be monitored by measuring hormone levels (e.g. free T4 and TSH) as clinically indicated.
Danish: Thyroidea og hypofysefunktionen bør monitoreres ved at måle hormonniveauer (fx T4 og TSH), hvis det er klinisk indiceret.
English: Appropriate monitoring of electrolytes (e.g. potassium, magnesium and phosphorus) and ECG should be performed at baseline and periodically during treatment, particularly in patients with severe gastrointestinal adverse drug reaction (see section 4.2).
Danish: Der skal udføres relevant monitorering af elektrolytter (f.eks. kalium, magnesium og fosfor) og EKG ved baseline og periodisk under behandlingen, særlig hos patienter med svære gastrointestinale bivirkninger (se pkt.
English: Day 8
Danish: Dag 8
English: Week 1 Days
Danish: Uge 1 Dage
English: - medicines to prevent blood clotting called anti-coagulants, such as warfarin or heparin.
Danish: - medicin mod blodpropper, som kaldes antikoagulatia, som fx warfarin eller heparin.
English: Table 7 includes adverse drug reactions that occur due to the addition of panobinostat to the bortezomib and dexamethasone combination.
Danish: Tabel 7 indeholder bivirkninger, som opstår på grund af tilføjelsen af panobinostat til kombinationen af bortezomib og dexamethason.
English: Very common Fatigue, oedema peripheral, pyrexia, asthenia Common
Danish: Meget almindelig Træthed, perifert ødem, pyreksi, asteni Almindelig
English: • muscle weakness, muscle spasms, unusual heartbeat (signs of changes in the level of potassium in the blood)
Danish: • muskelsvækkelse, muskeltrækninger, usædvanlig hjerterytme (tegn på ændringer i mængden af kalium i dit blod)
English: • reduced blood level of phosphate or sodium
Danish: • nedsat mængde fosfat eller natrium i blodet
English: Platelet count should be ≥100 x 109/l prior to initiating any cycle of treatment (see section 4.2).
Danish: Trombocyttallet bør være ≥100 x 109/l, før der initieres en given behandlingscyklus (se pkt.
English: The effect of renal impairment on the pharmacokinetics of panobinostat was assessed in a phase I study in 37 patients with advanced solid tumours with varying degrees of renal function.
Danish: Virkningen af nyreinsufficiens på panobinostats farmakokinetik blev vurderet i et fase I-forsøg hos 37 patienter med fremskredne solide tumorer og med varierende grader af nyreinsufficiens.
English: Farydak bortezomib and dexamethasone N=73
Danish: Farydak bortezomib og dexamethason N=73
English: Additionally, dose adjustment of bortezomib may be considered (see bortezomib SmPC and Table 3).
Danish: Desuden kan dosisjustering af bortezomib overvejes (se produktresuméet for bortezomib og tabel 3).
English: Reproduction toxicity
Danish: Reproduktionstoksisitet
English: Gastrointestinal haemorrhage, haematochezia, gastritis, cheilitis, abdominal distension, dry mouth, flatulence
Danish: Gastrointestinal hæmoragi, hæmatokesi, gastritis, cheilitis, abdominal distension, tør mund, flatulens
English: • fever, sore throat, or mouth ulcers due to infections (signs of a low level of white blood cells)
Danish: • feber, ondt i halsen eller sår i munden på grund af infektioner (tegn på et lavt antal hvide blodlegemer)
English: Reduce panobinostat dose to 10 mg in the first treatment cycle.
Danish: Nedsæt panobinostatdosis til 10 mg i den første behandlingscyklus.
English: Colitis, haematemesis, gastrointestinal pain
Danish: Ikke almindelig Colitis, hæmatemese, gastrointestinal smerte
English: Thyroid and pituitary function should be monitored by measuring hormone levels (e.g. free T4 and TSH) as clinically indicated (see section 4.2).
Danish: Thyroidog hypofyse-funktionen skal monitoreres ved at måle hormonniveauer (fx frit T4 og TSH) som klinisk indiceret (se pkt 4.2).
English: • swelling of the legs or arms
Danish: • hævede ben eller arme
English: Women of child-bearing potential should have a pregnancy test prior to the initiation of treatment with Farydak and must use a highly effective method of contraception during treatment and for three months after the last dose of Farydak.
Danish: Der skal udføres en graviditetstest på kvinder i den fertile alder før opstart af behandling med Farydak, og kvinden skal anvende yderst effektiv kontraception under behandlingen og i tre måneder efter den sidste dosis Farydak.
English: On days when you do not have to take Farydak, including the rest period in week 3, scratch the relevant empty cavities with your finger nail to help you keep track of your medication schedule.
Danish: Du kan skrabe de relevante tomme hulrum med din fingernegl på de dage, hvor du ikke behøver at tage Farydak, inklusive hvileperioden i uge 3, for at hjælpe dig med at holde styr på dit medicinregnskab.
English: - if you have heart or heartbeat problems, such as irregular heartbeat or a condition called long
Danish: - hvis du har problemer med hjertet eller hjerterytmen, fx uregelmæssig hjerterytme eller en tilstand, der hedder langt QT-syndrom.
English: Omit dose
Danish: Udelad dosis
English: • joint pain or inflammation
Danish: • ledsmerter eller ledbetændelse
English: More than half (57.2%) of the patients had undergone prior stem cell transplantation and 62.8% of the patients were relapsed after previous anti-neoplastic therapies (e.g. melphalan 79.6%, dexamethasone 81.1%, thalidomide 51.2%, cyclophosphamide 45.3%, bortezomib 43.0%, combined bortezomib and dexamethasone 37.8%, lenalidomide 20.4%).
Danish: Over halvdelen (57,2 %) af patienterne havde fået foretaget forudgående stamcelletransplantation, og 62,8 % havde recidiv efter tidligere antineoplastiske behandlinger (f.eks. melphalan 79,6 %, dexamethason 81,1 %, thalidomid 51,2 %, cyclophosphamid 45,3 %, bortezomib
English: The median PFS (95% CI) was 12.5 months (7.26, 14.03) in the panobinostat + bortezomib + dexamethasone arm and 4.7 months (3.71, 6.05) in the placebo + bortezomib + and dexamethasone arm [HR: 0.47 (0.31, 0.72)].
Danish: Den mediane PFS (95 % CI) var 12,5 måneder (7,26, 14,03) i panobinostat + bortezomib + dexamethason-armen og 4,7 måneder (3,71, 6,05) i placebo + bortezomib + dexamethason-armen [HR: 0,47 (0,31, 0,72)].
English: In addition, increased expression of the tumour suppressor gene p21CDKNIA (cyclin dependent kinase inhibitor 1/p21) gene, a key mediator of G1 arrest and differentiation, was triggered with panobinostat exposure.
Danish: Panobinostateksponering udløste desuden en øget ekspression af tumorsuppressorgenet p21CDKNIA (cyklinafhængig kinasehæmmer 1/p21)-gen, en vigtig mediator af G1-standsning ogdifferentiering.
English: Placebo bortezomib and dexamethasone N=74
Danish: Placebo bortezomib og dexamethason N=74
English: PAN=panobinostat BTZ= bortezomib Dex = dexamethasone
Danish: PAN=panobinostat BTZ= bortezomib Dex = dexamethason
English: - medicines used to treat cough, such as dextromethorphan.
Danish: - medicin til behandling af hoste, som fx dextromethorphan.
English: 33.3% patients in the panobinostat + bortezomib + dexamethasone arm and 10.3% patients in the placebo + bortezomib + dexamethasone arm received platelet transfusions during treatment.
Danish: Der var 33.3% patienter i panobinostat + bortezomib + dexamethason armen og 10,3% patienter i placebo + bortezomib + dexamethason armen, der fik trombocyttransfusion under behandling.
English: - medicines used to treat breast cancer, such as tamoxifen.
Danish: - medicin til behandling af brystkræft, som fx tamoxifen.
English: For patients >75 years of age, depending on the patient's general condition and concomitant diseases, an adjustment of the starting doses or schedule of the components of the combination regimen may be considered (see section 4.2).
Danish: For patienter >75 år kan justering af startdosis eller af planen for kombinationsbehandlingens komponenter overvejes afhængig af patientens almentilstand og samtidige sygdomme (se pkt.
English: Cardiac events (most frequently atrial fibrillation, tachycardia, palpitation and sinus tachycardia) were reported in 17.6% of panobinostat + bortezomib + dexamethasone-treated patients versus 9.8% of placebo + bortezomib + dexamethasone-treated patients and syncope events were reported in 6.0% versus 2.4%, respectively.
Danish: Hjertetilfælde (oftest atrieflimren, takykardi, palpitation og sinustakykardi) blev rapporteret hos 17,6% af panobinostat + bortezomib + dexamethason-behandlede patienter versus 9,8% af placebo + bortezomib + dexamethason-behandlede patienter og synkope tilfælde blev rapporteret hos henholdsvis 6,0% versus 2,4%.
English: Week 2 Days
Danish: Uge 2 Dage
English: The effect of hepatic impairment on the pharmacokinetics of panobinostat was evaluated in a phase I study, in 24 patients with solid tumours and with varying degrees of hepatic impairment.
Danish: Virkningen af leverinsufficiens på farmakokinetikken af panobinostat blev evalueret i et fase I-forsøg hos 24 patienter med solide tumorer og varierende grader af leverinsufficiens.
English: • severe headache, feeling weak or paralysis of limbs or face, difficulty speaking, sudden loss of consciousness (potential signs of nervous system problems such as bleeding or swelling in the skull or brain)
Danish: • kraftig hovedpine, svaghedsfølelse eller lammelse i arme, ben eller ansigt, talebesvær, pludselig besvimelse (mulige tegn på problemer i nervesystemet, som fx blødning eller hævelse i kraniet eller hjernen)
English: Platelets 10 x 109/l
Danish: Trombocytter 10 x 109/l
English: A dose escalation from 10 mg to 15 mg may be considered based on patient tolerability.
Danish: Dosiseskalering fra 10 mg til 15 mg kan overvejes baseret på patientens tolerabilitet.
English: In this subset of patients (N=147), the median duration of treatment was 4.5 months in the panobinostat + bortezomib + dexamethasone arm and 4.8 months in the placebo + bortezomib + dexamethasone arm.
Danish: I denne undergruppe af patienter (N=147) var den mediane behandlingstid 4,5 måneder i panobinostat + bortezomib + dexamethason-armen og 4,8 måneder i placebo + bortezomib + dexamethason-armen.
English: Consider dose escalation up to 15 mg in subsequent cycles based on patient tolerability.
Danish: Overvej dosiseskalering op til 15 mg i efterfølgende cyklusser baseret på patient-tolerabilitet.
English: • coughing up blood, oozing of bloody fluid from the nose (signs of bleeding in the lungs)
Danish: • ophostning af blod, blodig væske, der siver ud af næsen (tegn på blødning i lungerne)
English: Strong inducers are expected to have greater effects, and may reduce the efficacy of panobinostat, therefore the concomitant use of strong CYP3A4 inducers including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin and St. John's Wort (Hypericum perforatum), should be avoided.
Danish: Stærke inducere forventes at have en større virkning og kan nedsætte panobinostats effekt, hvorfor samtidig brug af stærke CYP3A4-inducere, herunder, men ikke begrænset til carbamazepin, phenobarbital, phenytoin, rifabutin, rifampicin og prikbladet perikon (Hypericum perforatum), skal undgås.
English: Iron oxide, black (E172) Propylene glycol (E1520) Shellac glaze
Danish: Jernoxid, sort (E172) Propylenglycol (E1520) Schellak-glasur
English: The median OS was 40.3 months in the panobinostat + bortezomib + dexamethasone arm and 35.8 months in the placebo + bortezomib + dexamethasone arm (Hazard ratio: 0.94 (95% CI: 0.78, 1.14)).
Danish: Den mediane OS var henholdsvis 40,3 måneder i panobinostat + bortezomib + dexamethason-armen og 35,8 måneder i placebo + bortezomib + dexamethason-armen (hazard ratio: 0,94 (95 % CI: 0,78; 1,14)).
English: • increased blood level of uric acid
Danish: • forhøjet mængde urinsyre i blodet
English: - if you notice any signs of a liver problem.
Danish: - hvis du bemærker et eller flere tegn på problemer med leveren.
English: Farydak 10 mg hard capsules Farydak 15 mg hard capsules Farydak 20 mg hard capsules
Danish: Farydak 10 mg hårde kapsler Farydak 15 mg hårde kapsler Farydak 20 mg hårde kapsler
English: Bortezomib dose on recovery to ≤ grade 1
Danish: Bortezomibdosis ved bedring til ≤ grad 1
English: - medicines used to treat irregular heartbeat, such as amiodarone, disopyramide, procainamide,
Danish: - medicin til behandling af uregelmæssig hjerterytme, som fx amiodaron, disopyramid,
English: Mild hypothyroidism was reported in patients treated with panobinostat + bortezomib + dexamethasone in Study D2308; some patients required treatment (see section 4.4).
Danish: Der blev rapporteret tilfælde af mild hypothyroidisme i patienter, der var behandlet med panobinostat + bortezomib + dexamethason i studiet D2308, og nogle patienter krævede behandling (se pkt.
English: 1.8- and 1.6-fold, respectively, and it cannot be excluded that the effect may be larger on a more sensitive CYP2D6 substrate.
Danish: Panobinostat øgede Cmax og AUC for dextromethorphan (et substrat for CYP2D6) henholdsvis 1,8 og 1,6 gange, og det kan ikke udelukkes, at effekten kan blive større med et mere sensitiv CYP2D6 substrat.
English: Very common Pancytopenia, thrombocytopenia, anaemia, leukopenia, neutropenia, lymphopenia
Danish: Meget almindelig Pancytopeni, trombocytopeni, anæmi, leukopeni, neutropeni, lymfopeni
English: QTcF >480 and <500 msec was recorded in 1.3% of patients and change from baseline of >60 msec was observed in 0.8% of patients.
Danish: blev registreret hos 1,3 % af patienterne, og ændring fra baseline på >60 msek.
English: Table 8 Progression-free survival in patients who received at least two prior regimens including bortezomib and an immunomodulating agent
Danish: Tabel 8 Progressionsfri overlevelse hos patienter, der tidligere har modtaget mindst 2 forudgående behandlingsregimer, herunder med bortezomib og en immunmodulator
English: In patients with hepatic impairment receiving concomitant medicinal products which are strong CYP3A4 inhibitors, treatment with panobinostat should be avoided due to lack of experience and safety data in this patient population.
Danish: Behandling med panobinostat bør undgås hos patienter med nedsat leverfunktion, der samtidigt er i behandling med lægemidler, som er stærke CYP3A4-hæmmere, på grund af manglende erfaring og sikkerhedsdata i denne patientgruppe.
English: • stomach or abdominal pain, nausea, diarrhoea, vomiting, black or bloody stools, constipation,
Danish: • mavesmerter, kvalme, diarré, opkastning, sort eller blodig afføring, forstoppelse, halsbrand,
English: Platelet transfusions may be required, if clinically indicated (see section 4.4).
Danish: Trombocyttransfusioner kan være nødvendigt, hvis det er klinisk indiceret (se pkt.
English: Liver function tests
Danish: Leverfunktionstests
English: Anti-emetic medicinal products with a known risk of QT prolongation such as dolasetron, granisetron, ondansetron and tropisetron should be used with caution (see section 4.4).
Danish: Antiemetisk medicin med en kendt risiko for QT-forlængelse, såsom dolasetron, granisetron, ondansetron og tropisetron, skal anvendes med forsigtighed (se pkt.
English: Adverse reaction
Danish: Delvist respons
English: Grade 3 despite anti-diarrhoeal medicinal product
Danish: Grad 3 trods lægemidler mod diarré
English: Grade 4 despite anti-diarrhoeal medicinal product
Danish: Grad 4 trods lægemidler mod diarré
English: • severely decreased urine output, swelling of the legs (signs of a kidney problem)
Danish: • stærkt nedsat urinmængde, hævede ben (tegn på et nyreproblem)
English: Titanium dioxide (E171) Brilliant blue FCF (E133) Iron oxide, yellow (E172)
Danish: Titandioxid (E171) Brilliant blue FCF (E133) Jernoxid, gul (E172)
English: In patients who take concomitant medicinal products which are strong CYP3A and/or Pgp inhibitors, including, but not limited to, ketoconazole, itraconazole, voriconazole, ritonavir, saquinavir, telithromycin, posaconazole and nefazodone, the dose of panobinostat should be reduced (see section 4.2).
Danish: Hos patienter, der tager samtidige lægemidler, som er stærke CYP3A- og/eller Pgp-hæmmere, herunder, men ikke begrænset til ketoconazol, itraconazol, voriconazol, ritonavir, saquinavir, telithromycin, posaconazol og nefazodon, bør panobinostat-dosis nedsættes (se pkt.
English: Fatigue and asthenia
Danish: Træthed og asteni
English: Other possible side effects If any of the side effects below becomes severe, tell your doctor, or your pharmacist.
Danish: Andre mulige bivirkninger Fortæl det til lægen eller på apoteket, hvis nogle af disse bivirkninger bliver alvorlige.
English: pain or burning feeling when passing urine, exaggerated sense of needing to pass urine, blood in urine (signs of an infection in the lungs or urinary tract)
Danish: kortåndethed eller åndedrætsbesvær, smerte eller svie ved vandladning, overdreven vandladningstrang, blod i urinen (tegn på en infektion i lungerne eller urinvejene)
English: Table 4 Recommended dose modifications for gastrointestinal toxicity Adverse drug reaction
Danish: Tabel 4 Anbefalede dosisændringer for gastrointestinal toksicitet Bivirkning Grad på behandlingsdagen
English: In the overall patient population PFS based on the full analysis set (FAS) was statistically significantly different between the treatment arms (stratified Log-rank test p<0.0001, with an estimated 37% risk reduction in the panobinostat + bortezomib + dexamethasone arm compared to the placebo + bortezomib + dexamethasone arm (Hazard ratio: 0.63 (95% CI: 0.52, 0.76)).
Danish: PFS baseret på full analysis set (FAS) var statistisk signifikant forskellig i de to behandlingsarme (stratificeret log-rank-test p<0,0001, med en estimeret risikoreduktion på 37 % i behandlingsarmen med panobinostat + bortezomib + dexamethason sammenlignet med behandlingsarmen med placebo + bortezomib + dexamethason (hazard ratio: 0,63 (95 % CI: 0,52; 0,76)), i den overordnede patientpopulation.
English: Agents whose plasma concentrations may be increased by panobinostat
Danish: Lægemidler, hvis plasmakoncentrationer kan forøges af panobinostat
English: On-treatment deaths not due to the study indication (multiple myeloma) were reported in 6.8% of panobinostat + bortezomib + dexamethasone-treated patients versus 3.2% of placebo + bortezomib + dexamethasone-treated patients.
Danish: Dødsfald under behandlingen, som ikke skyldtes forsøgets indikation (myelomatose), blev indberettet hos 6,8 % af de patienter, der fik panobinostat + bortezomib + dexamethason, versus 3,2 % af de patienter, der fik placebo + bortezomib + dexamethason.
English: Bortezomib dose on recovery to grade 2 thrombocytopenia
Danish: Bortezomib-dosis ved bedring til grad 2 thrombocytopeni
English: Panobinostat dose on recovery to ≤ grade 1
Danish: Panobinostatdosis ved bedring til ≤ grad 1
English: The primary target organs of toxicity following administration of panobinostat in rats and dogs were identified as the erythropoietic, myelopoietic and lymphatic systems.
Danish: De erythropoietiske, myelopoietiske og lymfatiske systemer blev identificeret som primære målorganer for toksisitet efter administration af panobinostat hos rotter og hunde.